Colorectal screening outreach Field checklist

Mailing a kit is not delivering screening.

This checklist is for population-health leaders, quality-improvement teams, preventive-care program managers, and operators adapting a comparable colorectal screening pathway. It turns one firsthand implementation into editable questions, tables, and launch checks. It is not Jefferson policy, a universal protocol, or medical advice; clinical decisions, eligibility rules, and follow-up ownership belong to the reader's local clinical and operational leaders.

The working source is Cole Lyons's 2023–2024 Jefferson implementation. Cole led the operational analysis and redesign under the Director of Population Health, created the working approach and patient materials, trained and supported the outreach team, monitored and reported the program, maintained the shipping system and spreadsheet, and handed the system off. This version was reviewed July 14, 2026 and incorporates current guidance without turning a local tactic into a requirement.

Three lanes to keep separate

Use these distinctions before copying a tactic into a local plan. A historical practice, a current clinical statement, and a local decision can sit next to one another without meaning the same thing.

Implemented in the Jefferson redesign

A firsthand description of the 2023–2024 operating bundle and its measured boundary: a recognizable envelope, detailed instructions, a QR video and MyChart route, reminders and support, shipping work, and delivery-aware spreadsheet exceptions.

Current guidance

General clinical guidance to confirm with the responsible clinical team and source: average-risk ages 45–75, individualized decisions at 76–85, annual FIT, stool DNA-FIT every three years after a negative result under current CDC/CMS operational guidance, and diagnostic colonoscopy after an abnormal stool result.

Decide locally

Choices that depend on the population, laboratory, people, contracts, systems, permissions, and care destination: denominator refresh, exclusions, reminder channels, replacement rules, result inbox, diagnostic-colonoscopy owner, repeat-interval owner, time window, and economic perspective.

1. Define the population and the handoffs

Start with a population that a clinical owner can defend. Current guidance concerns asymptomatic, average-risk adults ages 45–75. Screening decisions for adults ages 76–85 are individualized using health, prior screening, and preferences; routine screening stops after 85. People with symptoms or higher-risk histories need a different clinical pathway, not a quiet addition to an average-risk outreach denominator.

Record locally:

• the source and refresh date for the eligible denominator;
• how prior screening, surveillance, symptoms, family history, prior polyps, inflammatory bowel disease, and other higher-risk conditions are excluded or referred;
• who owns the referral when an outreach list is not a screening list; and
• which team receives questions that require clinical judgment.

Do not let a mailed-kit list become the definition of the population. An order, outreach attempt, or patient agreement is an intermediate event, not proof that the person belongs in the completed-screen denominator.

2. Define three kinds of completion

Track these layers separately. They answer different operational questions and have different owners.

1. Screening-test completion

   Count as complete: a valid laboratory result for the selected screening test.

   Do not substitute: an order, kit shipment, portal message, letter, reached patient, agreement, returned-but-unprocessable kit, or referral.

2. Abnormal-result follow-up

   Count as complete: diagnostic colonoscopy after an abnormal stool test, within a locally chosen and clinically reviewed time window.

   Do not substitute: a positive stool result alone, a cancer assumption, or repeating the stool test instead of arranging the diagnostic step.

3. Repeat-interval completion

   Count as complete: the next screening round at the appropriate interval after a negative result, with the modality and interval recorded.

   Do not substitute: treating one valid result as a lifetime close, or assuming the next round will happen without an owner and reminder path.

An abnormal stool result is not a cancer diagnosis. The stool result can close the screening-test layer while the clinical screening episode remains open until diagnostic colonoscopy is completed. Cole's Jefferson comparison ended at a valid FIT result; it did not measure diagnostic-colonoscopy completion, cancers, stage shift, lives saved, repeat-year adherence, or downstream savings.

3. Compare modalities without a universal ranking

Current guidance gives intervals; it does not tell every organization which pathway it can deliver best. Compare the whole operating path, including patient work, staff work, support, return logistics, abnormal follow-up, and the next interval.

For a short current-guidance summary: FIT is generally annual; stool DNA-FIT is repeated every 3 years after a negative result under current CDC/CMS operational guidance; and the normal average-risk screening-colonoscopy interval is 10 years. An abnormal stool test requires diagnostic colonoscopy.

The table is a comparison prompt, not a recommendation to rank one modality for everyone. Record the local clinical source and the exceptions that apply to the population you serve.

4. Make the kit a usable package

In the Jefferson baseline, staff hand-addressed a plain manila outer envelope with no Jefferson logo. Inside was a laboratory FIT package with sparse supplemental guidance. The redesign treated the package and the surrounding explanation as part of the care pathway:

1. Set the expectation

   Implemented: revised offer language and an explanatory voicemail said that a kit and instructions were coming.

   Ask locally: what should a person know before the envelope arrives, and which single next action should be unmistakable?

2. Make the sender recognizable

   Implemented: a recognizable Jefferson-branded envelope replaced the anonymous outer presentation.

   Ask locally: which locally authorized sender and return address will make the package recognizable?

3. Make print sufficient

   Implemented: a substantially more detailed plain-language guide explained the kit and next steps.

   Ask locally: can someone complete the task with the printed guide alone, including large-type or translated versions where needed?

4. Offer video without requiring it

   Implemented: a QR code pointed to an instructional video; the same video route was available in MyChart.

   Ask locally: is a short, captioned video useful, and what is the non-digital path when a person cannot or does not want to scan it?

5. Provide reachable support

   Implemented: the redesigned pathway included planned reminders and staff support.

   Ask locally: what phone, portal, language, or accessibility route can answer a practical question without returning the person to a generic queue?

6. Own the return

   Implemented: the shipping workflow was maintained as part of the redesign.

   Ask locally: who supplies labels, postage, packaging, collection instructions, and a clear return destination, and how is a failed or delayed return noticed?

The envelope, QR video, voicemail, and guide were local components of one combined bundle. The Jefferson comparison cannot isolate an effect for any one component, and these tactics are adaptable options rather than independently proven clinical interventions.

5. Support, remind, return, and handle exceptions

Choose a reminder sequence that a person can understand and a team can carry. Do not publish a made-up day-by-day cadence. Cole does not confidently recall a fixed calendar schedule; the Jefferson spreadsheet used observed delivery speed and successful-return timing, including ZIP-code-related patterns, to flag an outstanding kit after the period in which a return was still likely. That was empirical staff decision support, not a confirmed formula, automated contact engine, or predictive clinical model.

Use these prompts when designing the local sequence:

• explain what is arriving, why it matters, and how to get help;
• make the printed instructions and non-digital fallback useful without a portal login;
• record shipping and return events so staff can see an exception rather than guess;
• choose reminder channels and timing with the outreach team, then test whether the sequence is workable;
• offer a replacement or laboratory contact path for a lost, damaged, expired, or invalid kit;
• treat a returned-but-unprocessable or invalid kit as not a valid result until the replacement path produces a valid result;
• route an abnormal result to the named diagnostic-colonoscopy owner, not back to a generic reminder queue; and
• record the reason for a closeout or requeue so a missed return is not silently labeled patient failure.

6. Assign staff work and measure the effort

Name the handoff before launch. One person or team may hold several roles, but the role must be visible.

Useful measures include valid-result completion, invalid-kit rate, abnormal-result follow-up, repeat-interval completion, touches per valid result, staff time per valid result, exception age, and the share of cases with an assigned owner. None is a universal target. Keep each number with its denominator, observation window, modality, and population.

7. Read the Jefferson comparison at its actual boundary

At Jefferson, the FIT comparison used two sequential, nonrandomized cohorts of approximately 800 patients each, in the same plan and year, with matching or accounting for plan, demographics, time window, outreach channel, and outreach staff. Both cohorts used a 90-day follow-up window and the same endpoint: a valid resulted FIT. The full case study describes the implementation and its operating lessons.

Rounded valid-result completion was approximately 18–23 percent in the baseline cohort and approximately 45 percent with the redesigned bundle. These internal measurements are not a target for another organization, and the comparison cannot attribute the difference to one envelope, QR code, reminder, or instruction. The study did not measure diagnostic-colonoscopy completion, cancers, stage shift, lives saved, repeat-year adherence, or savings.

The Jefferson project provides one operating example. Define and measure the denominator, window, endpoint, and follow-up layers for the local program.

8. Treat economics as a time-horizon question

Prevention can create value on a longer horizon than the organization paying for it can reliably capture. That mismatch can make a clinically valuable pathway look less attractive in a short-term budget. This is an economic framing, not an assertion about any payer's policy or motive.

Keep these questions separate:

9. Readiness checks before launch

Copy this list into the local launch record and attach an owner to every unchecked item.

Current guidance sources

Review these sources with the responsible clinical team when this artifact is reused. They support general guidance, not Jefferson facts or outcomes:

• CDC: Colorectal cancer screening
• CMS130v14: Colorectal Cancer Screening, 2026 performance period
• USPSTF: Colorectal cancer screening recommendation

Return to the Jefferson Colorectal Screening Case for the project context.